Abstract 149P
Background
To develop novel anti-cancer therapeutics, we have used a reverse rational approach and searched for human HLA class I molecules known to induce autoimmunity as a surrogate marker for potential anti-cancer activity. HLA-B57 is one example of an HLA class I molecule described to target LILRB receptors in these studies. Here we demonstrate the proof of concept of a bispecific optimised HLA-Fc fusion conjugated to a SIRPa protein which shows potent in vitro anti-tumor efficacy through its multimodal binding of LILRB1, LILRB2 and CD47 receptors. This novel modality of HLA/SIRPa Bispecifics has the unique characteristic of targeting myeloid cells and the ability to be directed to tumor sites by targeting the CD47 on cancer cells.
Methods
Rational guided protein engineering and transient protein production in CHO was conducted. Affinity determination was measured by SPR/BLI. Binding to cells expressing the receptors was assessed by flow cytometry. Potency was measured using CD47/SIRPa reporter cell lines. Evaluation of in vitro safety was performed by binding assessment to red blood cells and hemagglutination induction. In vitro efficacy studies were performed for macrophage phagocytosis and NK cell cytotoxicity against cancer cells. Ex-vivo efficacy is currently being assessed using primary NSCLC tumor biopsies and measuring tumor cell killing and activation of immune cell markers.
Results
HLA/SIRPa Bispecifics were expressed as IgG4 Fc-fusion proteins in a 2+2 format. Affinity to LILRB1/LILRB2 and CD47 receptors are in low nM range. By optimization of the affinity of the c-terminal SIRPa we can show an enhanced safety profile compared to competitor CD47 targeting molecules through reduced binding to red blood cells and reduced hemagglutination. Reporter cells demonstrate that bispecifics effectively inhibit the interaction of CD47 with SIRPa. In vitro efficacy data shows that macrophage phagocytosis was enhanced by optimizing specific properties of the SIRPa arm.
Conclusions
HLA/SIRPa bispecifics are novel multi-functional agents that potentiate anti-tumor immunity through the interaction of multiple immune checkpoint receptors on one side and may function to engage macrophages towards cancer cells on the other side.
Legal entity responsible for the study
ImmunOs Therapeutics AG.
Funding
ImmunOs Therapeutics AG.
Disclosure
A. Rafiei: Non-Financial Interests, Personal, Full or part-time Employment: ImmunOs Therapeutics AG. O. Marroquin Belaunzaran: Financial Interests, Personal, Officer: ImmunOs Therapeutics AG. All other authors have declared no conflicts of interest.
Resources from the same session
26P - Liquid biopsy as promising source of plasma extracellular vesicle biomarkers of response to Cabozantinib (CABO) plus Durvalumab (DURVA) in advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) patients (the Phase 2 ARCADIA trial)
Presenter: Veronica Huber
Session: Poster Display
27P - Peripheral biomarker analysis in patients with advanced urothelial carcinoma (UC) after platinum chemotherapy treated with Cabozantinib (CABO) plus Durvalumab (DURVA): preliminary analysis from the Phase 2 ARCADIA trial.
Presenter: Francesco Sgambelluri
Session: Poster Display
28P - 3-year follow-up analysis of disease-free survival in CheckMate 274 by PD-L1 expression using tumor cell and combined positive scoring algorithms
Presenter: Frank Stenner-Liewen
Session: Poster Display
30P - CD4+ T cells within the tumor microenvironment are an independent predictor of recurrence, but do not improve the performance of a predictive model in oral squamous cell carcinoma
Presenter: Sangeeta Bisheshar
Session: Poster Display
31P - Characterization of pre-exhausted / exhausted state of CD8+ T cells in HRAS mutant head and neck carcinomas (HNSCCs). Implications for response to immune checkpoint blockade (ICB).
Presenter: Ioannis Kotsantis
Session: Poster Display
32P - Tumor-agnostic plasma assay for circulating tumor DNA predicts outcome in recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with a PD-1 inhibitor
Presenter: Natasha Honoré
Session: Poster Display
34P - Heterogeneous response to Immune Checkpoint Inhibitors in metastatic melanoma patients - assessment of lesion-level response with 18F-FDG PET/CT
Presenter: Katja Strasek
Session: Poster Display